Expert Interview
A second look at the potential of IL-23 inhibitors like SKYRIZI (risankizumab) in patients with ulcerative colitis and the top-line results from the Phase 3 COMMAND maintenance study.
Ticker(s): ABBVInstitution: Self- Employed
- board certified GI physician in practice for over 35 years
- treats approx 30 patients with Ulc Colitis
- familiar with the Command 3 trial on Skyrizi in UC.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
